Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis

Background: Immune checkpoint inhibitors (ICIs) have been an emerging treatment strategy for advanced triple-negative breast cancer (TNBC). Some studies have shown that high expression of programmed death-ligand 1 (PD-L1) can achieve a better response of clinical efficacy. However, the efficacy of I...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Yingjie, Yan, Xin, Wang, Chao, Cao, Hui, Liu, Guangxuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755205/
https://www.ncbi.nlm.nih.gov/pubmed/36532783
http://dx.doi.org/10.3389/fphar.2022.1004821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755205/
https://www.ncbi.nlm.nih.gov/pubmed/36532783
http://dx.doi.org/10.3389/fphar.2022.1004821

Ejemplares similares